In contrast, under section 1860D-14B(a) of the Act, CMS must report rebate amounts to each manufacturer of a Part D rebatable drug no later than 9 months after the end of each applicable period, except that for the first two applicable periods (that is, October 1, 2022, to September 30, 2023, and October 1, 2023, to September 30, 2024), CMS has until December 31, 2025, to invoice manufacturers for Part D inflation rebates
They shared their belief that non-physician practitioners and post-acute care providers should be included in the definition, as they have a role to potentially improve outcomes and reduce costs
Introduction: The Synergistic Peptide Paradigm
this potential risk has not been evaluated in clinical studies
3 Tkalcevic VI, et al